These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 12661124)

  • 1. [More care for a limited budget; a case for a better use of the efficiency criteria].
    de Winter LJ; Heerema NC
    Ned Tijdschr Geneeskd; 2003 Feb; 147(8):363-4. PubMed ID: 12661124
    [No Abstract]   [Full Text] [Related]  

  • 2. [More care for a limited budget; a case for a better use of the efficiency criteria].
    Rutten FF; Brouwer WB
    Ned Tijdschr Geneeskd; 2002 Nov; 146(47):2254-8. PubMed ID: 12481524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [More care for a limited budget; a case for a better use of the efficiency criteria].
    Bleijenberg G; Prins J; Severens JL; van der Meer JW
    Ned Tijdschr Geneeskd; 2003 Jan; 147(3):134; author reply. PubMed ID: 12577774
    [No Abstract]   [Full Text] [Related]  

  • 4. [The cost per year of life gained: trends and internal contradictions].
    Smulders YM; Thijs A
    Ned Tijdschr Geneeskd; 2006 Nov; 150(45):2467-70. PubMed ID: 17137090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Health Council recommendation on the 'Contours of the basic package'].
    ten Velden GH; Mackenbach JP
    Ned Tijdschr Geneeskd; 2004 Jan; 148(2):97-101. PubMed ID: 14753133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Frequently asked questions about basic insurance].
    Tijdschr Diergeneeskd; 2005 Sep; 130(18):561-3. PubMed ID: 16189937
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for colorectal cancer: which test can we afford?
    Lansdorp-Vogelaar I; van Ballegooijen M; Kuipers EJ
    Z Gastroenterol; 2008 Apr; 46 Suppl 1():S38-40. PubMed ID: 18368641
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical treatment pathways: successful due to standardization. Better cooperation, clear responsibilitties, cost analysis and more quality].
    Roeder N;
    Urologe A; 2003 Apr; 42(4):599-601. PubMed ID: 12830798
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic barriers to implementation of innovations in health care: is the long run-short run efficiency discrepancy a paradox?
    Adang EM; Wensing M
    Health Policy; 2008 Dec; 88(2-3):236-42. PubMed ID: 18471924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Criteria and procedures for determining benefit packages in health care. A comparative perspective.
    Gress S; Niebuhr D; Rothgang H; Wasem J
    Health Policy; 2005 Jul; 73(1):78-91. PubMed ID: 15911059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Psychiatric psychotherapeutic psychosomatic treatment by the hospital: framework for the development of a multi-sector budget for regional mandatory care].
    Kruckenberg P; Beine K; Aderhold V; Bock T; Bührig M; Deister A; Driessen M; Elsässer-Gaismaier HP; Grampp P; Greve N; Heinz A; Heinze M; Heisler M; Küthmann A; Kunze H; Lucht M; Niedermeyer U; Obliers W; Schütze W; Stock M
    Psychiatr Prax; 2009 Jul; 36(5):246-9. PubMed ID: 19582663
    [No Abstract]   [Full Text] [Related]  

  • 13. [The personal budget--a new system of benefits for disabled people].
    Wacker E
    Rehabilitation (Stuttg); 2009 Feb; 48(1):4-14. PubMed ID: 19206032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Legislation by BMGS on evaluation of cost effectiveness].
    GFB
    Chirurg; 2004 Mar; 75(3):M76. PubMed ID: 15080093
    [No Abstract]   [Full Text] [Related]  

  • 15. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economizing by the health care system. The costs and value of nursing].
    Baartmans P
    Krankenpfl Soins Infirm; 2004; 97(2):20-1. PubMed ID: 15040221
    [No Abstract]   [Full Text] [Related]  

  • 17. [AOK pays for bureaucracy relief].
    MMW Fortschr Med; 2006 Apr; 148(14):56-7. PubMed ID: 16669285
    [No Abstract]   [Full Text] [Related]  

  • 18. [Procedures and methods of benefit assessments for medicines in Germany - a comment - letter no. 1].
    Koch K; Lange S
    Dtsch Med Wochenschr; 2009 Feb; 134(7):317-9; author reply 320. PubMed ID: 19197816
    [No Abstract]   [Full Text] [Related]  

  • 19. Is there a business case for quality in The Netherlands? A critical analysis of the recent reforms of the health care system.
    Custers T; Arah OA; Klazinga NS
    Health Policy; 2007 Jul; 82(2):226-39. PubMed ID: 17070956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance.
    Yang BM; Bae EY; Kim J
    Health Aff (Millwood); 2008; 27(1):179-87. PubMed ID: 18180493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.